Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing demand for effective and long-lasting immunity
3.2.1.2 Growing prevalence of infectious diseases and pandemics
3.2.1.3 Increased government and private funding for vaccine development
3.2.2 Industry pitfalls and challenges
3.2.2.1 High costs and lengthy development timelines
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Pipeline analysis
3.8 Gap analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)
5.1 Key trends
5.2 Adjuvant emulsions
5.3 Pathogen components
5.4 Saponin-based adjuvants
5.5 Particulate adjuvants
5.6 Other product types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
6.1 Key trends
6.2 Intramuscular
6.3 Subcutaneous
6.4 Oral
6.5 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)
7.1 Key trends
7.2 Infectious diseases
7.3 Cancer
7.4 Other diseases
Chapter 8 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)
8.1 Key trends
8.2 Human vaccines
8.3 Veterinary vaccines
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Agenus
10.2 Allergy Therapeutics
10.3 Aurorium
10.4 Brenntag Biosector
10.5 Croda International
10.6 CSL Limited
10.7 Dynavax Technologies Corporation
10.8 EuBiologics
10.9 GSK plc
10.10 Merck KGaA
10.11 Novavax
10.12 OZ Biosciences
10.13 Riboxx GmbH
10.14 Seppic
10.15 SPI Pharma
